Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nipent pentostatin: Phase I/II data; marketed to treat hairy cell leukemia

In a U.S. Phase I/II trial, 6 of 9 patients

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE